Cellectar Biosciences Inc... (CLRB)
NASDAQ: CLRB
· Real-Time Price · USD
4.59
0.17 (3.85%)
At close: Aug 15, 2025, 2:18 PM
3.85% (1D)
| Bid | 4.56 |
| Market Cap | 12.3M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.54M |
| EPS (ttm) | -18.9 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | -0.36 |
| Analyst | Buy |
| Ask | 4.64 |
| Volume | 273,603 |
| Avg. Volume (20D) | 491,945 |
| Open | 4.40 |
| Previous Close | 4.42 |
| Day's Range | 4.22 - 4.72 |
| 52-Week Range | 4.22 - 68.70 |
| Beta | 0.42 |
About CLRB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLRB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLRB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-31.65%
Cellectar Biosciences shares are trading lower aft...
Unlock content with
Pro Subscription
2 months ago
+16.58%
Cellectar Biosciences shares are trading higher after the company announced initial results from the CLOVER-2 Phase 1 clinical trial evaluating iopofosine I 131 in relapsed/refractory pediatric high-grade glioma patients.
